These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28456943)

  • 21. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.
    Trinh TD; Smith JR; Rybak MJ
    Pharmacotherapy; 2019 Nov; 39(11):1077-1094. PubMed ID: 31487056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence.
    Tsegka KG; Voulgaris GL; Kyriakidou M; Falagas ME
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):657-668. PubMed ID: 32397774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment.
    Folgori L; Bielicki J; Heath PT; Sharland M
    Curr Opin Infect Dis; 2017 Jun; 30(3):281-288. PubMed ID: 28306563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
    Shorr AF; Pogue JM; Mohr JF
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.
    Burgos RM; Rodvold KA
    Future Microbiol; 2019 Apr; 14():461-475. PubMed ID: 30854892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria.
    Dinh A; Salomon J; Bru JP; Bernard L
    Scand J Infect Dis; 2012 Mar; 44(3):182-9. PubMed ID: 22176655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neonatal Sepsis: Mortality and Morbidity in Neonatal Sepsis due to Multidrug-Resistant (MDR) Organisms: Part 1.
    Wattal C; Kler N; Oberoi JK; Fursule A; Kumar A; Thakur A
    Indian J Pediatr; 2020 Feb; 87(2):117-121. PubMed ID: 31828600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.
    Antonello RM; Di Bella S; Maraolo AE; Luzzati R
    Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1117-1126. PubMed ID: 33604721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fosfomycin: an old--new antibiotic.
    Raz R
    Clin Microbiol Infect; 2012 Jan; 18(1):4-7. PubMed ID: 21914036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.
    Falagas ME; Kastoris AC; Karageorgopoulos DE; Rafailidis PI
    Int J Antimicrob Agents; 2009 Aug; 34(2):111-20. PubMed ID: 19403273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose treatment of acute cystitis with fosfomycin tromethamine.
    Stein GE
    Ann Pharmacother; 1998 Feb; 32(2):215-9. PubMed ID: 9496408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.
    Poulakou G; Bassetti M; Righi E; Dimopoulos G
    Future Microbiol; 2014; 9(9):1053-69. PubMed ID: 25340835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extracellular concentrations of fosfomycin in lung tissue of septic patients.
    Matzi V; Lindenmann J; Porubsky C; Kugler SA; Maier A; Dittrich P; Smolle-Jüttner FM; Joukhadar C
    J Antimicrob Chemother; 2010 May; 65(5):995-8. PubMed ID: 20228081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is experimental endotoxaemia in humans suitable for simulating antibiotic pharmacokinetics in sepsis and septic shock? A pilot study using the model compound fosfomycin.
    Sauermann R; Mayer-Helm BX; Petsch M; Popovic M; Thallinger C; Joukhadar C
    Int J Antimicrob Agents; 2008 Mar; 31(3):291-2. PubMed ID: 18160265
    [No Abstract]   [Full Text] [Related]  

  • 39. [Fosfomycin, an old antibiotic with new possibilities].
    Dijkmans AC; Kuiper SG; Burggraaf J; Mouton JW; Wilms EB; Touw DJ; Stevens J; van Nieuwkoop C; Kamerling IMC
    Ned Tijdschr Geneeskd; 2017; 161():D973. PubMed ID: 28612692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Revival of selected well-tried antibiotics. Special features of the antiinfective agents penicillin G, fosfomycin, aztreonam and colistin].
    Lipp HP
    Med Monatsschr Pharm; 2012 Oct; 35(10):367-77. PubMed ID: 23094579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.